Evidence map›Paper›PMID 32453732›Full record

ArticlePLoS biology2020

The evolution of the type VI secretion system as a disintegration weapon.

William P J Smith, Andrea Vettiger, Julius Winter, Till Ryser, Laurie E Comstock, Marek Basler, Kevin R Foster

Abstract read
In one paragraph

Article in PLoS biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Science advances · 2025
    Article
  19. Decoding resistance in the age of T6SS warfare.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

William P J SmithDepartment of Biochemistry, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-9270-7614
Andrea VettigerBiozentrum, University of Basel, Basel, Switzerland.ORCID 0000-0002-1245-0987
Julius WinterBiozentrum, University of Basel, Basel, Switzerland.ORCID 0000-0001-6702-1330
Till RyserBiozentrum, University of Basel, Basel, Switzerland.ORCID 0000-0001-5911-3542
Laurie E ComstockBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Marek BaslerBiozentrum, University of Basel, Basel, Switzerland.
Kevin R FosterDepartment of Biochemistry, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-4687-6633

Funding

Secreted antimicrobial proteins of the intestinal BacteriodalesR01AI093771 · NIAID · UNIVERSITY OF CHICAGO · PI LAURIE E COMSTOCK · 2012 to 2026
$5.1M
NIAID NIH HHS R01 AI093771Wellcome Trust 209397/Z/17/Z
6 · The paper itself

Abstract

The type VI secretion system (T6SS) is a nanomachine used by many bacteria to drive a toxin-laden needle into other bacterial cells. Although the potential to influence bacterial competition is clear, the fitness impacts of wielding a T6SS are not well understood. Here we present a new agent-based model that enables detailed study of the evolutionary costs and benefits of T6SS weaponry during competition with other bacteria. Our model identifies a key problem with the T6SS. Because of its short range, T6SS activity becomes self-limiting, as dead cells accumulate in its way, forming "corpse barriers" that block further attacks. However, further exploration with the model presented a solution to this problem: if injected toxins can quickly lyse target cells in addition to killing them, the T6SS becomes a much more effective weapon. We tested this prediction with single-cell analysis of combat between T6SS-wielding Acinetobacter baylyi and T6SS-sensitive Escherichia coli. As predicted, delivery of lytic toxins is highly effective, whereas nonlytic toxins leave large patches of E. coli alive. We then analyzed hundreds of bacterial species using published genomic data, which suggest that the great majority of T6SS-wielding species do indeed use lytic toxins, indicative of a general principle underlying weapon evolution. Our work suggests that, in the T6SS, bacteria have evolved a disintegration weapon whose effectiveness often rests upon the ability to break up competitors. Understanding the evolutionary function of bacterial weapons can help in the design of probiotics that can both establish well and eliminate problem species.

Indexed as

AntibiosisEvolution, MolecularModels, BiologicalAcinetobacterEscherichia coliMicrofluidicsSingle-Cell AnalysisType VI Secretion SystemsType VI Secretion Systems

Identifiers

PMID32453732
PMCPMC7274471

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.